TNF and irritable bowel syndrome: If we could consider the increase of regulatory T cells as a predictive factor of response to biological therapy, patients who receive anti-TNFα agents after a shorter period of time since diagnosis (“top-down” strategy [37]) may have more benefits from this therapy, confirming the possibility to change the natural course of IBD.